Musculoskeletal Diseases Nervous System Diseases Stroke
Conditions
Interventions
Combination of VRT and VSE integrated with task-specific activities.
Task-specific activities alone as an intervention approach
Sponsors
University of Pretoria
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a) Patients that suffered either an ischaemic or haemorrhagic stroke (Blanton et al, 2006) as clinically diagnosed by a medical specialist. Information on type of stroke will be obtained from the patients¿ medical records. b) Male and female patients from the age group 19 ¿ 84 years (The SASPI Project Team, 2004). c) Patients that are in the sub-acute phase following the stroke, are able to follow instructions (Lennon et al, 2006) and have the capacity to provide informed consent (Loetscher et al, 2015). d) Patients that presented with visual impairments and central vestibular dysfunction identified during phase 1 of the study will be recruited to participate in phase 2 of the study.
Exclusion criteria
Exclusion criteria: a) Severe dementia, identified by implementing the Mini-Mental State Examination (MMSE). (Patients must have a score of seven or higher on the MMSE) (Hafsteinsdóttir, 2005). b) History of an organic disorder or major psychiatric impairment (Blanton et al, 2006). c) Other co-morbid disease or disability such as cancer or amputation that will prevent or limit assessment of the patients and their, participation or follow-up over a period of twenty (20) weeks (Robertson et al, 2002; Blanton et al, 2006; Lennon et al, 2006). d) Positive Dix-Hallpike test (to exclude BPPV). e) Dix-Hallpike test: Because the Dix-Hallpike test and CRT (Epley) manoeuvre require head rotation of 45° and extension of 20° to 30°; patients with a history of neck surgery, recent neck trauma, severe rheumatoid arthritis, atlanto-axial and occipito-atlantal instability, cervical myelopathy or radiculopathy, carotid sinus syncope, Chiari malformation and vascular dissection syndromes are excluded from the study (Herdman & Tusa, 2007). f) Participation in other pharmacological or rehabilitation intervention studies which can lead to confounding of the results of this study (Blanton et al, 2006). g) Any adverse effects within the period of twenty (20) weeks will be documented.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional ability | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual impairments;Central vestibular dysfunction;Cognitive function;Visual-perceptual function;Residual oculomotor visual performance;Functional balance;Ability to modify gait in response to changing task demands;Level of anxiety and/or depression;Participation in physical activity | — |
Countries
South Africa
Contacts
Public ContactAndoret van Wyk
University of Pretoria
Outcome results
None listed